Biomerica preliminary Q2 revenue $4.6M (+238% YoY); backlog $4M; InFoods trial data due Jan 2022

BIOMERICA INC

2022-Q2 EPS reported -$0.21 revenue$5,908,687

Revenue approximately $4.6M for Q2 ended Nov 30, 2021, up 238% from $1.4M a year ago, driven by COVID test demand.
Operating loss expected between $0.9M and $1.3M; logistics constraints and higher shipping costs hurt margins.
Backlog of unfilled orders exceeds $4.0M entering Q3; cash balance over $7M, partly from prepayments.
InFoods IBS clinical trial data collection complete; topline results expected by end of January 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.